Suppr超能文献

“睫状体光凝二极管”。经巩膜二极管激光睫状体光凝术治疗晚期难治性青光眼。

"Cyclodiode". Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma.

作者信息

Bloom P A, Tsai J C, Sharma K, Miller M H, Rice N S, Hitchings R A, Khaw P T

机构信息

Glaucoma Service, Moorfields Eye Hospital, London, England.

出版信息

Ophthalmology. 1997 Sep;104(9):1508-19; discussion 1519-20. doi: 10.1016/s0161-6420(97)30109-2.

Abstract

PURPOSE

To analyze the results of intraocular pressure (IOP) reduction by diode laser contact cyclophotocoagulation ("cyclodiode") in cases of advanced glaucoma refractory to alternative treatments.

METHODS

Two hundred and ten eyes of 195 patients, ages 1 to 89 years (mean, 51 years) were followed for 3 to 30 months (mean, 10 months) after cyclodiode treatment.

RESULTS

More than one treatment was given in 102 eyes (49%), and the overall mean number of treatments given per eye was 1.75 (range, 2-5). Mean pretreatment IOP was 34.1 mmHg (+/-10.6 mmHg). At last follow-up, mean IOP was 20.1 mmHg (+/-9.3 mmHg), and mean total medications was reduced from 2.3 to 1.7. Mean final IOP was lowest in patients with silicone oil glaucoma (17.3 mmHg), and the mean reduction in IOP was greatest in patients with neovascular glaucoma (23.9 mmHg). At last follow-up, visual acuity was worse than before treatment in 29% of eyes, unchanged in 60%, and better in 11%. Overall success rate (IOP < 22 mmHg) was 66% at a mean follow-up of 10 months. Phthisis occurred in one eye (0.5%), and chronic hypotony (0 mmHg < IOP < 5 mmHg for > 3 months) in a further two eyes (1%). Corneal graft decompensation followed treatment in two eyes, macular pucker occurred in one eye, and combined hyphema/vitreous hemorrhage in one patient.

CONCLUSIONS

Diode laser cycloablation is relatively safe and effective at controlling IOP in eyes with advanced refractory glaucoma in the short and medium term. With the treatment parameters used, multiple applications may be needed.

摘要

目的

分析二极管激光接触性睫状体光凝术(“睫状体光凝”)降低晚期青光眼眼压的效果,这些青光眼对其他治疗方法无效。

方法

195例年龄在1至89岁(平均51岁)患者的210只眼在接受睫状体光凝治疗后随访3至30个月(平均10个月)。

结果

102只眼(49%)接受了不止一次治疗,每只眼接受治疗的总体平均次数为1.75次(范围为2至5次)。治疗前平均眼压为34.1 mmHg(±10.6 mmHg)。在最后一次随访时,平均眼压为20.1 mmHg(±9.3 mmHg),平均总用药量从2.3种减少至1.7种。硅油性青光眼患者的平均最终眼压最低(17.3 mmHg),新生血管性青光眼患者的眼压平均降低幅度最大(23.9 mmHg)。在最后一次随访时,29%的眼视力比治疗前差,60%的眼视力无变化,11%的眼视力改善。在平均10个月的随访中,总体成功率(眼压<22 mmHg)为66%。一只眼(0.5%)发生眼球痨,另外两只眼(1%)发生慢性低眼压(眼压在0 mmHg <眼压<5 mmHg持续超过3个月)。两只眼治疗后发生角膜移植失代偿,一只眼发生黄斑皱襞,一名患者发生前房积血/玻璃体积血。

结论

二极管激光睫状体光凝术在短期和中期控制晚期难治性青光眼眼压方面相对安全有效。使用这些治疗参数时,可能需要多次应用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验